Noxopharm Ltd. · ASX:NOX
Noxopharm — Investor Presentation (September 2016)
23 slides from Noxopharm's investor presentation, Sep 12, 2016
Slide 1: Noxopharm Corporate Presentation, September 2016
ASX RELEASE 12 September 2016 For personal use only NOXOPHARM CORPORATE PRESENTATION, SEPTEMBER 2016 ASX: NOX Ahead of a roadshow commencing 12 September in Asia, Noxopharm has today Noxopharm released an updated corporate presentation incorporating expansion of its NOX66 Limited clinical program in
Slide 2: Corporate Presentation, Sept 2016
For personal use only Corporate Presentation, Sept 2016 ASX: NOX 1
Slide 3: The problem
For personal use only The problem q Once a cancer becomes metastatic, death is the usual eventual outcome q Treatment fails because cancer cells have become resistant to standard therapies q Death occurs because the patient runs out of treatment options q Resistance to chemotherapy and radiotherapy
Slide 4: Our objective
For personal use only Our objective q To bring to market a proprietary drug that overturns cancer cell resistance mechanisms in a potent and highly selective way q To restore responsiveness to standard chemotherapy and radiotherapy q To provide treatment options for the elderly and frail, and the gr
Slide 5: Our means: NOX66
For personal use only Our means NOX66 An innovative form of idronoxil q Idronoxil is the most potent inhibitor of cancer cell resistance mechanisms q Idronoxil works for both chemotherapy and radiotherapy q Idronoxil is highly selective for cancer cells q NOX66 - designed to ensure idronoxil reaches
Slide 6: Our vision
For personal use only Our vision q To have a first-in-class drug meeting a substantial unmet clinical need q To dominate the field in major drug territories with IP protection q To become a global biopharmaceutical company with a suite of drugs focused on cancer cell resistance mechanisms 5
Slide 7: Idronoxil overturns resistance
For personal use only Idronoxil Cisplatin Carboplatin Overturns resistance to all Paclitaxel Docetaxel Gemcitabine Doxrubicin major cytotoxic drugs Topotecan Overturns resistance in all Ovarian Prostate Melanoma Head & neck forms of cancers tested Pancreatic Laboratory No evidence of toxicity Animal
Slide 8: Clinical Program: Chemotherapy
For personal use only Clinical Program Chemotherapy Cytotoxic chemotherapy main front-line therapy for most forms of life-threatening cancers 7
Slide 9: Objectives: Cytotoxic chemotherapy
Objectives For personal use only Cytotoxic chemotherapy • Achieve responses in cancers with inherent resistance (eg. pancreatic cancer, malignant melanoma, brain cancer) • Achieve responses in cancers with acquired resistance • Lower dosages of chemotherapy to provide safer therapy • Make chemothera
Slide 10: Phase I/II Clinical Study design
Phase I/II Clinical Study For personal use only Design Number of sites 2 Territory Georgia Commence Q4 2016 Patients Solid tumours that have failed to respond to standard therapies Number of patients Minimum 15. Maximum 35 Phase 1a 14-days NOX66 monotherapy Phase 1b 6 months combination therapy: NOX
Slide 11: Phase I/II Clinical Study potential outcomes
Phase I/II Clinical Study For personal use only Potential outcomes Safety • Confirmation that NOX66 does not exacerbate carboplatin toxicity Clinical benefit • Reversal of resistance to carboplatin in cancers with inherent drug resistance (eg. pancreatic cancer, lung cancer) • Reversal of resistance
Slide 12: Clinical Program: Radiotherapy
For personal use only Clinical Program Radiotherapy Radiation therapy Front-line or second-line therapy for many common forms of cancer 11
Slide 13: Phase Ib Clinical Study design/potential outcomes
Phase Ib Clinical Study For personal use only Design/potential outcomes Status • 2 proposed studies • Currently in planning • Projected start 4Q16 & 1Q17 Proposed design • Specific tumour type per study • Palliative radiotherapy to selective lesions + NOX66 • 2 weeks Rx. • 2-3 months response assess
Slide 14: Indicative timelines
Indicative timelines For personal use only Proposed clinical study timeline 4Q 2016 1Q 2017 2Q 2017 3Q 2017 4Q 2017 1Q 2018 Chemotherapy Study Phase 1a Phase 1b Phase 2a Radiotherapy Study 1 Radiotherapy Study 2 13
Slide 15: IP position
IP position For personal use only Idronoxil Structure not patentable. First described by G. Kelly in 1994. Patent lodgement Family of provisional patents lodged. Claims revolve around innovative formulation designed to block Phase 2 metabolism and conserve bio-activity 2nd and 3rd generation R&D pro
Slide 16: Experienced team
Experienced team For personal use only Experienced Team Graham Kelly PhD Dr Ian Dixon PhD, MBA Managing Director Non-Executive Director • Head of research team at University of Sydney that discovered idronoxil in • Over 20 years’ experience in the biotechnology and medical device industries and 1992
Slide 17: Key metrics
Key metrics For personal use only Shares outstanding 75M : 30M free; 45M escrowed (July 2019) Other 22.5M options ($0.30) (2021) 10M performance shares ($50M market cap) (2021) Cash position $6M IPO (9 Aug 2016) $5M (Sept 2016) 16
Slide 18: Concluding Remarks
For personal use only 17 Concluding Remarks
Slide 19: Company Aim
For personal use only Company Aim Noxopharm Aim Improved response rates in most forms of solid cancers To overturn resistance to the Allow drug and radiotherapy dose rates to be lowered to reduce toxicity most commonly-used Permit effective therapy in chemotherapies elderly/frail patients & radiothe
Slide 20: Value drivers
For personal use only Value DriversValue drivers Large Lack of Clinic- Expeditious market size competition Experience ready clinical plan No current drug or known drug Over 20 years’ Substantial Indication of in development experience with Phase 1 study unmet need for efficacy with same this technol
Slide 21: Key Messages
For personal use only Key Messages Resistance to chemotherapy/radiotherapy remains the most pressing and largest problem facing patients No drug has come to market that successfully treats this problem WE EXPECT TO KNOW WITHIN 12 MONTHS OF THE SUCCESS OF OUR MISSION IN RADIOTHERAPY WE EXPECT TO KNOW
Slide 22: Disclaimer
For personal use only Disclaimer This presentation has been prepared by Noxopharm Limited a company proposed to be listed as [ASX:NOX] (NOX or the Company). It should not be considered as an offer or invitation to subscribe for or purchase any shares in NOX or as an inducement to make an offer or
Slide 23: Contact
For personal use only Contact Dr Graham Kelly Chief Executive Officer graham.kelly@noxopharm.com 22